Valneva SE Product Market Size & Share 2015

1
Valneva SE - Product Pipeline Review - 2015
Published on October - 2015
2
.
Report Overview
About Valneva SE - Product Pipeline Review -
2015 Research Beam added report on Valneva SE
Product Pipeline Review - 2015. Summary Global
Markets Directs, Valneva SE Product Pipeline
Review - 2015, provides an overview of the
Valneva SE s Valneva SE research and
development focus. This report provides comp
rehensive information on the current therapeutic
developmental pipeline of Valneva SE s, complete
with comparative analysis at various stages,
therapeutics assessment by drug target, mechanism
of action (MoA), route of administration (RoA)
and molecule type. It also reviews latest
updates, and featured news and press releases,
along with special features on late-stage and
discontinued projects. Get Full Details On
http//www.researchbeam.com/valneva-se-product-pip
eline-review-2015-market
3
.
Report Overview
Global Markets Directs report features
investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000
indications. The report is built using data and
information sourced from Global Markets Directs
proprietary databases, Company/University
websites, SEC filings, investor presentations and
featured press releases from company/university
sites and industry-specific third party sources,
put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes
periodic updation following a stringent set of
processes that ensures that all the profiles are
updated with the latest set of information.
Additionally, processes including live news
deals tracking, browser based alert-box and
clinical trials registries tracking ensure that
the most recent developments are captured on a
real time basis. The report enhances decision
making capabilities and help to create effective
counter strategies to gain competitive advantage.
It strengthens RD pipelines by identifying new
targets and MOAs to produce first-in-class and
best-in-class products. Note Certain sections
in the report may be removed or altered based on
the availability and relevance of data for the
indicated disease.
4
.
Report Overview
Scope The report provides brief overview of
Valneva SE including business description, key
information and facts, and its locations and
subsidiaries The report reviews current pipeline
of Valneva SE s human therapeutic division and
enlists all their major and minor projects The
report features product description and
descriptive mechanism of action for key pipeline
products along with the products developmental
history and major milestones Special feature on
out-licensed and partnered product portfolio The
report summarizes all the dormant and
discontinued pipeline projects Latest company
statement Latest news and deals relating to the
Valneva SE s pipeline products  
5
Report Overview

• Reasons to buy
•  Evaluate Valneva SE s strategic position with
  total access to detailed information on its
  product pipeline
• Assess the growth potential of Valneva SE in its
  therapy areas of focus
• Identify new drug targets and therapeutic classes
  in the Valneva SE s RD portfolio and develop
  key strategic initiatives to reinforce pipeline
  in those areas
• Exploit in-licensing opportunities by identifying
  windows of opportunity to fill portfolio gaps
• Develop strategic initiatives by understanding
  the focus areas of Valneva SE and exploit
  collaboration and partnership opportunities
• Identify emerging players with potentially strong
  product portfolio and create effective
  counter-strategies to gain competitive advantage
• Plan mergers and acquisitions effectively by
  identifying the most promising pipeline of
  Valneva SE
• Develop and design in-licensing and out-licensing
  strategies by identifying prospective partners
  with the most attractive projects to enhance and
  expand business potential and Scope
• Explore the dormant and discontinued projects of
  Valneva SE and identify potential opportunities
  in those areas

6
Table Of Contents
Table of Contents 2List of Tables 4List of
Figures 4Valneva SE Snapshot 5Valneva SE
Overview 5Key Information 5Key Facts 5Valneva
SE - Research and Development Overview 6Key
Therapeutic Areas 6Valneva SE - Pipeline Review
8Pipeline Products by Stage of Development
8Pipeline Products - Monotherapy 9Pipeline
Products - Partnered Products 10Partnered
Products/Combination Treatment Modalities 11
7
Table Of Contents
Pipeline Products - Out-Licensed Products
12Out-Licensed Products/Combination Treatment
Modalities 13 Valneva SE - Pipeline Products
Glance 14Valneva SE - Clinical Stage Pipeline
Products 14Phase II Products/Combination
Treatment Modalities 14Valneva SE - Early Stage
Pipeline Products 15Preclinical
Products/Combination Treatment Modalities
15Discovery Products/Combination Treatment
Modalities 16Valneva SE - Drug Profiles
17VLA-43 17Product Description 17Mechanism of
Action 17RD Progress 17Vaccine for Undisclosed
Indication 19
8
Table Of Contents
Product Description 19Mechanism of Action 19RD
Progress 19VLA-84 20Product Description
20Mechanism of Action 20RD Progress 20VLA-15
21Product Description 21Mechanism of Action
21RD Progress 21Antibodies for Pneumococcus
Infections 22 Enquiry about this report _at_
http//www.researchbeam.com/valneva-se-product-pip
eline-review-2015-market/enquire-about-report

9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/valneva-se-product-pip
eline-review-2015-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] E-MAIL
sales_at_researchbeam.com